Senloytics, dasatinib plus quercetin, reduce kidney inflammation, senescent cell abundance, and injury while restoring geroprotective factors in murine diabetic kidney disease.

Xiaohui Bian, Zachary K Snow, Caroline J Zinn, Anastasia L Bratulin, Khaled M Elhusseiny, Tamar Tchkonia, James L Kirkland, Yi Zhu, Sundeep Khosla, Seo Rin Kim, Lilach O Lerman, LaTonya J Hickson

Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA; Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address: [email protected]. · pubmed

Paper

Abstract

Maladaptive inflammation and cellular senescence contribute to diabetic kidney disease (DKD) pathogenesis and represent important therapeutic targets. Senolytic agents selectively remove senescent cells and reduce inflammation-associated tissue damage. In our pilot clinical trial in patients with DKD, the senolytic combination dasatinib plus quercetin (D + Q) reduced systemic inflammation, senescent cell abundance, and macrophage infiltration in fat. However, D + Q senotherapeutic effects on diabetic kidney injury, senescence, inflammation, and geroprotective factors have not been established.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that the senolytic combination dasatinib plus quercetin reduces kidney inflammation and senescent cell abundance in diabetic kidney disease. This research targets cellular senescence and inflammation, which are key contributors to aging and age-related diseases, making it relevant to longevity research.

Author of this paper? Send a correction.